• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Vical, Inc.

NASDAQ:VICL

$2.85 -$0.06 (-2.06%)

REAL-TIME: Last trade at

Vical announces publication of herpes simplex vaccine mouse study data

Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data

Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data

Vical reports net income for Q1

Vical's CEO Presents at Bank of America Merrill Lynch Health Care Conference Call (Transcript)

Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference

Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference

Vical to Present at Upcoming Investor Conferences

Vical (VICL) Files $150M Mixed Shelf

Vical files $150M mixed securities shelf

Vical's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Vical: An Update On My $3 Biotech Lottery Ticket

Vical, Inc. (VICL) Tops Q1 Expectations by 8c/Share

Vical reports Q1 EPS 0c, consensus (8c)

Vical Reports First Quarter 2012 Financial Results and Progress in Key Development Programs

Credit Suisse Assumes Coverage on Vical (VICL) at Outperform

Vical coverage assumed with an Outperform at Credit Suisse

Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results

Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results

Global Gene Therapy Industry

Astellas, Vical finalize design for phase-3 cytomegalovirus vaccine trial

Vical (VICL), Astellas Pharma Finalize TransVax Phase 3 Design

Vical, Astellas advance toward Phase 3 trial of TranxVax CMV vaccine

Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical

Vical's Vaxfectin Adjuvant Used In Novel Malaria Vaccine

Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant

Vical announces collaborations developed Vaxfectin-formulated DNA

Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant

Vical's Allovectin: Why Hasn't The Trial Been Stopped?

Vical (VICL) Announces Start Of Clinical Trial For DNA Vaccine With Vaxfectin

Vical announces initiation of clinical trial for DNA vaccine using Vaxfectin

U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant

Vical to Present at Upcoming Investor Conferences

Vical's CEO Hosts at Citi 2012 Global Health Care Conference (Transcript)

Vical to Present at Upcoming Investor Conferences

Vical to Present at Upcoming Investor Conferences

Canaccord Genuity Maintains a 'Buy' on Vical (VICL); Still Attractive Risk/Reward

Vical's Herpes Vaccine Headed To The Clinic

Vical's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Vical reports Q4 EPS (9c) vs. consensus (12c)

See More Articles...